



EVITRADE APPOINTS INVESTOR RELATIONS FIRM - Updated

VANCOUVER, BC, Monday March 4, 2019 – EVITRADE Health Systems Corp. (CSE: EVA, OTCQB: EVAHF) (the “Company”) is pleased to announce the appointment of Parabolic Communications Inc. as the Company’s Investor Relations strategy firm.

EViTrade is pleased to announce the appointment of Parabolic Communications Inc. as its lead for investor relations strategy and content development for the Company’s on-line presence. With over ten years providing private and public enterprises with communication strategies and support; Parabolic is a boutique firm committed to assisting their clients with engagement and retention solutions for their client’s businesses on both the public markets side and within the sales channels that the Company is focusing on.

As EViTRADE executes its business objectives as a vertically integrated “Health System with a CBD focus, management is pleased to continue to have Parabolic Communications on-board to help deliver the Company’s story and successes to investors and the health and wellness community. The Company has engaged Parabolic’s services on a month to month basis at a cost of five thousand dollars per month.

EViTrade continues to fulfill its commitment to elevate the human condition through advanced technologies for medical solutions. The Company’s Health System may be leveraged to improve health outcomes by monitoring and recording the effects of CBD on your cardiovascular system. Therein adapting it to become one of the world’s first CBD Health Monitoring Systems.

Contact:

EVITRADE Health Systems Corp.
(formerly Auxellence Health Corporation)

Email info@evahealthsystems.com or ceo@auxellence.com

Website <http://www.evahealthsystems.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

US OTC Markets (OTCQB): <http://www.otcm Markets.com/stock/EVAHF/news>

About EVITRADE Health (CSE: EVA, OTCQB: EVAHF)

EVITRADE Health Systems Corp. (formerly, Auxellence Health Corporation), is a technology company specializing in the Health and Life Sciences sector looking to deliver effective personalized health solutions with a higher degree of predictability and consistency.

The Company is focused on the following areas to help improve health: personalized medical care (including CBD usage monitoring and effects on the cardiovascular system), molecular biology, nutraceutical solutions and genetic tailoring.

Through its subsidiaries' focus on technologies involved in extracting and purifying CBD extracts for its personalized healthcare system, the Company may be the first to offer a complete quality assured, vertically integrated "CBD Health System" for monitoring and recording the effects of CBD on your cardiovascular system.

Disclaimers

This news release contains forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators and on the OTC Markets website which is posted on www.sedar.com, <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>, and <http://www.otcmarkets.com/stock/EVAHF/filings>. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), or any other regulatory authority accepts responsibility for the adequacy or accuracy of this release. The Company does not undertake to update this news release unless required by applicable law.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.